Ustekinumab
Stelara (ustekinumab) is an antibody pharmaceutical. Ustekinumab was first approved as Stelara on 2009-01-15. It is used to treat crohn disease and psoriatic arthritis in the USA. It has been approved in Europe to treat crohn disease, psoriasis, and psoriatic arthritis. The pharmaceutical is active against interleukin-12 subunit beta.
| Trade Name | Stelara |
|---|---|
| Common Name | Ustekinumab |
| ChEMBL ID | CHEMBL1201835 |
| Indication | crohn disease, psoriasis, psoriatic arthritis |
| Drug Class | Monoclonal antibodies: interleukins as targets|monoclonal antibodies: fully human, neural indications |
